

---

## Anti-Human Cep55 Purified

**Catalog Number:** 14-9809

**Also known as:** Centrosomal protein, c10orf3

**RUO: For Research Use Only. Not for use in diagnostic procedures.**

---

### Product Information

**Contents:** Anti-Human Cep55 Purified  
**Catalog Number:** 14-9809  
**Clone:** EMRC10-11-55  
**Concentration:** 0.5 mg/mL  
**Host/Isotype:** Mouse IgG1, k

REF

**Formulation:** aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer  
**Temperature Limitation:** Store at 2-8°C.



LOT



**Batch Code:** Refer to vial

**Use By:** Refer to vial

**Contains sodium azide**

---

### Description

The monoclonal antibody EMRC10-11-55 recognizes the human centrosomal protein (Cep55). Cep55 is a 55 kDa microtubule-bundling protein that is found throughout the cell but specifically localizes to the mitotic spindle during metaphase and the midbody during anaphase. Cep55 is necessary for the completion of cytokinesis, a process that if dysregulated promotes tumorigenesis via a mechanism of aneuploidy and chromosomal instability. Cep55 is downstream of the transcription factor FOXM1, and has been found to be overexpressed in a head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma, breast cancer, colorectal carcinoma (CRC), and in secondary metastatic sites. Expression has been found to correlate with severity of disease and as a cancer biomarker is prognostic of poor outcome in breast cancer. Cep55 is expressed at very modest levels in normal tissue, but is more prominent in testis and thymus.

### Applications Reported

This EMRC10-11-55 antibody has been reported for use in western blotting and immunohistochemical staining of formalin-fixed paraffin embedded tissue sections.

### Applications Tested

This EMRC10-11-55 antibody has been tested by immunohistochemistry on FFPE human breast cancer tissue using low pH antigen retrieval at less than or equal to 10 ug/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

### References

Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, Nakatsugawa M, Tamura Y, Kamiguchi K, Tsuruma T, Terui T, Ishitani K, Hashino S, Wang Q, Greene MI, Hasegawa T, Hirata K, Asaka M, Sato N. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. *Exp Mol Pathol*. 2011 90(1):55-60.

Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriya K, Nakazawa E, Harada K, Takasu H, Tamura Y, Kamiguchi K, Asanuma H, Tsuruma T, Terui T, Ishitani K, Ohmura T, Wang Q, Greene MI, Hasegawa T, Hirata K, Sato N. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. *J Immunother*. 2009 32(5):474-85.

### Related Products

00-4952 IHC/ICC Blocking Buffer - High Protein

00-4954 20X TBS Wash Buffer for IHC/ICC

00-4955 IHC Antigen Retrieval Solution – Low pH (10X)

14-4714 Mouse IgG1 K Isotype Control Purified (P3.6.2.8.1)

---

Not for further distribution without written consent.

Copyright © 2000-2012 eBioscience, Inc.

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • [www.ebioscience.com](http://www.ebioscience.com) •  
[info@ebioscience.com](mailto:info@ebioscience.com)